Sahajanand Medical Technologies IPO — GMP Today, Price Band & Dates
Sahajanand Medical Technologies IPO GMP Today
The current grey market premium (GMP) of the Sahajanand Medical Technologies IPO is ₹17. GMP reflects unofficial demand for the shares before listing and moves with market sentiment and subscription numbers. This figure updates automatically every hour.
Key Details
| IPO Name | Sahajanand Medical Technologies |
|---|---|
| Type | Mainboard |
| IPO Dates | 15-19 Oct 2026 |
| Price Band | ₹344 |
| GMP Today | ₹17 |
| Estimated Listing | ₹361 (4.94%) |
| Status | Closed |
Live data last refreshed: 16/11/2026, 17:26:32 IST
FAQ
What is the GMP of Sahajanand Medical Technologies IPO today?
Sahajanand Medical Technologies IPO GMP today is ₹17.
What are the Sahajanand Medical Technologies IPO dates?
Sahajanand Medical Technologies IPO dates: 15-19 Oct 2026.
Is Sahajanand Medical Technologies a Mainboard or SME IPO?
Sahajanand Medical Technologies is a Mainboard IPO.
Does GMP guarantee listing gains?
No. GMP is an unofficial, unregulated indicator and can change quickly. Always evaluate the company's fundamentals before investing.
About Sahajanand Medical Technologies
Sahajanand Medical Technologies Limited is an R&D-driven company incorporated in 2001 that develops Class III and Class C/D medical devices with an emphasis on Vascular Intervention and Structural Heart segments. Headquartered in Surat and Mumbai, the company operates three manufacturing facilities—two in India and one in Thailand. It markets its products globally, reaching 65 countries in the three months ended June 30, 2026, and 77 countries in Fiscal 2026, using direct, hybrid, and distributor-led models.
Business Model
The company earns revenue primarily through the sale of medical device products categorized into Vascular Intervention devices, Structural Heart devices, and other products including traded goods, renal stents, and peripheral drug-coated balloons. It serves customers such as hospitals, interventional cardiologists, surgeons, healthcare professionals, purchasing agents, government agencies, and distributors across India, Europe, and the Rest of the World.
Financial Performance
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from operations | 9,016.04 | 10,248.79 | 12,105.04 |
| EBITDA | 1,100.47 | 1,280.21 | 1,706.55 |
| Profit after tax | -73.54 | 251.52 | 690.82 |
| Net worth | 5,263.03 | 5,452.32 | 6,160.51 |
| Total borrowings | 1,752.69 | 2,249.57 | 2,695.26 |
| EBITDA margin | 12.21% | 12.49% | 14.10% |
| PAT margin | -0.82% | 2.45% | 5.71% |
Figures as disclosed in the DRHP/RHP filed with the stock exchange. Source: offer document.
Objects of the Issue
- Carry out the Offer for Sale of up to 13,822,116 Equity Shares aggregating up to ₹ [●] million by the Selling Shareholders.
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
Promoters
The promoters of the company are Bhargav Dhirajlal Kotadia (Managing Director and CEO), Dhirajlal Vallabhbhai Kotadia (Chairman Emeritus), Priyanka Dhirajlal Cohen, and Shree Hari Trust, a private family trust.
Strengths
- Technologically advanced products in segments with high entry barriers.
- Proven research and development capabilities across product categories and platform technologies.
- Leadership in India and key international markets across products.
- Deep global sales and marketing presence leading to fast growth in diversified international markets.
- Diversified, integrated, and efficient manufacturing facilities accredited by regulatory authorities.
- Proven M&A and strategic collaborations playbook alongside an experienced leadership team backed by reputed institutional investors.
Key Risks
- Extensive regulatory requirements in applicable jurisdictions, and any adverse action could negatively impact the ability to offer products.
- Manufacturing facilities are subject to risks including quality control issues, infrastructure disruptions, and obsolete plant and machinery.
- Requirement to obtain, renew, and maintain statutory and regulatory permits, licenses, and approvals.
- Dependence on continued supply and cost variation of raw materials and components, with top suppliers contributing a significant share of purchases.
- High dependence on revenues from Vascular Intervention devices, particularly the Supraflex Cruz product.
- Regulatory uncertainty associated with the pricing of medical devices could affect marketing, pricing, and demand.
Points to Weigh
- Investors should evaluate the company's heavy revenue concentration in Vascular Intervention devices and specifically the Supraflex Cruz product line.
- The company is subject to extensive regulatory requirements, periodic audits, and pricing uncertainties across multiple international jurisdictions.
- Total borrowings stood at ₹2,695.26 million as of March 31, 2026, which investors should factor into the company's financial leverage.
- The IPO consists entirely of an Offer for Sale by existing shareholders, meaning the company will not receive any proceeds from the fresh issue.